Полуколичественный экспресс-метод определения С3 и С4 компонентов системы комплемента

Список литературы

1. Гланц С. Медико-биологическая статистика. Пер. с англ. М., Практика, 1998. — 459 с.
2. Козлов JI.B., Шибанова Е. Д., Зинченко А. А. Образование классической СЗ-конвертазы в ходе активации альтернативного пути комплемента человека. //Биохимия. 1987. — т.52. — № 4. — С.660−665.
3. Козлов J1.B. Особенности функционирования протеиназ комплемента. //Биоорганическая химия. 1994. Т.20. — № 3. — С.229−241.
4. Козлов JI.B., Кудряшова Л. П., Иванова И. В. Система комплемента больных ревматоидным артритом в зависимости от проводимой лекарственной терапии. //Клин. Мед. 1994. — т.5. — С.43−47.
5. Козлов JI.B. Белки системы комплемента: активация и регуляция. //Иммунология. 1997. — № 2. — С.8−13.
6. Козлов JI.B. Исследование функциональной активности компонентов и факторов системы комплемента человека. //Вопросы медицинской химии. 2002. — т.48. — № 6. — С.624−631.
7. Романов С.В. Определение функциональной активности компонентов С2, СЗ и факторов В и D комплемента человека: Дисс. .канд. биол. наук.: М.:РГБ. 2003.
8. Терминология белков системы комплемента. //Бюлл. ВОЗ. 1968. -Т.59. — № 6. — С.935.
9. Терминология белков альтернативного пути системы комплемента. //Бюлл. ВОЗ. 1981. — Т.59. — № 3. — С.377−379.
10. O.Adam A., Petit J. F., Lefrancier P., Lederer E. Muramil peptides. Chemical structure, biological activity and mechanism of action. //Molecular and Cellular Biochem. 1981. — vol.41. — P.27−47.
11. Ahmed A.E.E., Peter J.B. Clinical utility of complement assessment. //Clin. Diagn. Lab. Immunol. 1995. Sept. — P.509−517.
12. Alexander R. L. Comparison of radial immunodiffusion and laser nephelometry for quantitating some serum proteins. //Clin. Chem. 1980. -vol.26.-P.314−317.
13. Arbuckle M.R., McClain M.T., Rubertone M. V. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. //N. Engl. J. Med. -2003. vol.349. -P.1526−1533.
14. Atkins С J. Chido and Rodgers: a serological study of their variations on the red cells and plasma. MSc thesis, Brunei University, 1985.
15. Atkinson J.P., Chan A.C., Karp D.R. Origin of the fourth component of complement related Chido and Rodgers blood group antigens. //Complement. 1988. — vol.5. — P.65−76.
16. Avrameas S. Historical Background of the Invention of EIA and ELISA. //Clin. Chem. -2006. vol.52 (7). — P. 1430−1431.
17. Awdeh Z.I., Alper C.A. Inherited structural polymorphism of the fourth component of human complement. //Proc. Natl. Acad. Sci. USA. 1980. -vol.77.-P.3576−3580.
18. Barba G., Rittner C., Schneider P.M. Genetic basis of human complement C4A deficiency: detection of a point mutation leading to nonexpression. //J. Clin. Invest. 1993. -vol.91.-P.1681−1686.
19. Barba G.M.R., Braun-Heimer L., Rittner C., Schneider P.M. A new PCR-based typing of the Rodgers and Chido antigenic determinants of the fourth component of human complement. //Eur. J. Immunogenet. 1994. — vol.21. -P.325−339.
20. Barrington R., Zhang M., Fischer M., Carroll M. C. The role of complement in inflammation and adaptive immunity. //Immunol. Rev. 2001. — vol.180. — P.5−15.
21. Becherer J. D., Alsenz J., Servis C. Cell surface proteins reacting with activated complement components. //Complement Inflamm. — 1989. — vol.6. -P.142−165.
22. Bjorge L. The complement system structure, activation, regulation and function. //Tidsskr. Nor. Laegeforen. — 1999. — vol.119, № 2. — P.226−233.
23. Belr K.T., Carroll M.C., Porter R.R. The structural basis of the multiple forms of human complement component C4. //Cell. 1984. — vol.36. -P.907−914.
24. Belr K.T., Yu C.Y., Carroll M.C., Porter R.R. Polymorphism of human component complement C4. //Immunogenetics. 1985. — vol.21. — P.173−180.
25. Bentley D. R., Campbell R. D. C2 and factor B: structure and genetics. //Biochem. Soc. Symp. 1986. — vol.51. — P.7−18.
26. Bergelson J. M., Chan M., Solomon K. R. Decay-accelerating factor (CD55), a glycosylphosphatinylinositol-anchored complement regulatory protein, is a receptor for several echoviruses. //Proc. Natl. Acad. Sci. U.S.A. 1994. -vol.91.-P.6245−6249.
27. Black S., Kushner I., Samols D. C-reactive Protein. //J. Biol. Chem. 2004.- vol.279. P.48 487−48 490.
28. Blom A. M., Kask L., Dahlb B. Structural requirements for the complement regulatory activities of C4-binding protein. //J. Biol. Chem. 2001. -vol.276.-P.27 136−27 144.
29. Blom A. M., Webb J., Villoutreix В. O., Dahlback B. A cluster of positively charged amino acids in the C4BP alpha chain is crucial for C4b binding and factor I cofactor function. //J. Biol. Chem. — 1999. — vol.274. — P.19 237−19 245.
30. Boccuni P., Del Vecchio L., Di Norto R., Rotoli B. Glycosyl phosphoinositol (GPI)-anchored molecules and the pathogenesis of paroxysmal nocturnal hemoglobinuria. //Crit. Rev. Oncol. Hematol. 2000. — vol.33. — P.25−43.
31. Bordet J. Sur l’agglutination et la dissolution des globules rouges par le serum d’animaux injectes de sang defibrine. //Ann. De l’lnst. Pasteur. 1898.1. XII —P.688−695.
32. Bordet J., Gengou O. Sur l’existencede substances sensibilisatrices dans la plupart des serums antimicrobiens. //Ann. De l’lnst. Pasteur. — 1901. XV -P.289−303.
33. Bossuyt X., Blanckaert N. Evaluation of interferences in rate and fixed-time nephelometric assays of specific serum proteins. //Clin. Chem. 1999. -vol.45 -P.62−67.
34. Braun L., Schneider P.M., Giles C.M. Null alleles of human complement C4: evidence for pseudogenes at the C4A locus and for gene conversion at the C4B locus. //J. Exp. Med. 1990. — vol.171. — P. 129−140.
35. Bronfenbrenner J., Noguchi H. A biochemical study of the phenomena known as complement-splitting: first paper: splitting of the complement associated with globulin precipitation. //J. Exp. Med. 1912. -vol.15. -P.598−624.
36. Вшип-Petersen G., Lamm L.U., Jakobsen B.K., Kristensen T. Genetics of complement C4: two homoduplication haplotype C4S C4S and C4 °F C4 °F in a family. //Hum. Genet. 1982. — vol.61. -P.36−38.
37. Buchner H. bber die bakterientijdtende Wirkung des zellenfreien Blutserums. //Zbl. Bact. I Abt. Orig. 1889. — Bd. 5, S. 817, Bd. 6, S. 1.
38. Caliezi C., Wuillemin W. A., Zeerleder S. Cl-esterase inhibitor: an antiinflammatory agent and its potential use in the treatment of diseases other than hereditary angioedema. //Pharmacol. Rev. 2000. — vol.52, № 1. — P.91−112.
39. Carroll M.C., Belt Т., Palsdottir A., Porter R.R. Structure and organization of C4 genes. //Phil. Trans. R. Soc. London B. 1984. — vol.306. — P.379. — 388.
40. Carroll M.C., Palsdottir A., Belt K.T., Porter R.R. Deletion of complement C4 and steroid 21-hydroxylase genes in the HLA class III region. //EMBO J. 1985. — vol.4. -P.2547−2552.
41. Carroll M.C., Alper C.A. Polymorphism and molecular genetics of human C4. //Br. Med. Bull. 1987. — vol.43. -P.50−65.
42. Carroll M.C. The complement system in regulation of adaptive immunity. //Nature Immunol. 2004. — vol. 5, № 10. — P. 168−176.
43. Carroll M.C. The complement system in B-cell regulation. //Mol. Immunol. -2004.-vol.41 -P.141−146.
44. Chaplin H. Jr. Review: the burgeoning history of the complement system 1888−2005. //Immunohematology 2005. — vol.21 -P.85−93.
45. Choi N. H., Mazda Т., Tomita M. A serum protein SP40,40 modulates the formation of the membrane attack complex of complement on erythrocytes. //Mol. Immunol. 1989. — vol.26. — P.835−840.
46. Chrispeels J., Grabbe J., Stradinann B. Rapid purification of the fourth component of human complement and production of C4-specific monoclonal antibodies including isotype-specific ones Abstract. //Complement. 1987. -vol.4. -P.142.
47. Cooper N. R., Muller-Eberhard H. J. The reaction mechanism of human C5 in immune hemolysis. //J. Exp. Med. 1970. — vol.132. — P.775−793.
48. Cooper N. R., Jensen F. C., Welsh R. M., Oldstone M. B. A. Lysis of RNA-tumor viruses by human serum: direct antibody dependent triggering of the classical complement pathway. //J. Exp. Med. 1976. — vol.144, № 4. -P.970−984.
49. Cooper N. R. The classical complement pathway: activation and regulation of the first complement component. //Adv. Immunol. 1985. — vol.37. -P.151−216.
50. Cramer D. V. Natural antibodies and the host immune responses to xenografts. //Xenotransplantation. 2000. — vol.7, № 2. — P.83−92.
51. Daniels G.L. Human Blood Groups, 2nd ed. Blackwell Science, 2002.
52. Daha M. R., Fearon D. Т., Austen K. F. C3 nephritic factor (C3NeF): stabilization of fluid phase and cell-bound alternative pathway convertase. //J Immunol. 1976.- vol. 116.-P. 1−7.
53. Dahl M. R., Thiel S., Willis A. C. Mannan-binding lectin associated serine protease 3 (MASP-3): a new component of the lectin pathway of complement activation,^{mmunopharmacology.} 2000. — vol.49. — P.79.
54. Day N. К. B, Gewurz, H., Johannsen, R. Complement and complement-like activity in lower vertebrates and invertebrates. //J. Exp. Med. 1970. — vol.132. -P.941−950.
55. Dick J. F. On the origin and action of hemolytic complement. //J. Infect. Dis. -1913.-vol.12.-P.lll.
56. Dodds A.W., Law S.-K.A. Porter R.R. The purification and properties of some less common allotypes of the fourth component of human complement. //Immunogenetics. 1986. — vol.24. — P.279−285.
57. Douglas G.N. Complement system. Calbiochem-Behring. Division of Hoechst Corporation. 1983. — P.3−26.
58. Dunckley H., Gatenby P.A., Hawkins B. Deficiency of CA is a genetic determinant of systemic lupus erythematosus. //J. Immunogenet. 1987. — vol.14. -P.209−218.
59. Duval C.W., Gurd E.B. Experimental immunity with reference to the bacillus of leprosy: part I. A study of the factors determining infection in animals. //J. Exp. Med. 1911 — vol.14. -P.181−195.
60. I.Edwards-Moulds J., Arnett F.C., Moulds J.J. Increased incidence of Rodgers negative individuals observed in systemic lupus erythematosus patients Abstract. //Transfusion. 1989. — vol.29. — 16S.
61. Ehrlich, P. Experimentelle untersuchungen bber immumtAt. //Deutsche med. Wchnschr.-1891.-XVII.: 976 P. 1218.
62. Ehrlich I., Morganroth J. Veber haemolysine. //Berl. Klin. Wschr. 1900 -vol.37.-P.453.
63. Embers J. A., Jagels M.A., Hugli Т.Е., 1998. //In: Volankis J. E., Frank M. M. eds. Characterization of complement anaphylatoxins and their biological responses. Marcel Dekker, New York, 1998. P.241−284.
64. Engvall E., Perlmann P. Enzyme-linked immunosorbent assay (ELISA). Quantitative assay of immunoglobulin G. //Immunochemistry. 1971. -vol.8. -P.871−874.
65. Fahey J. L., McKelvey E. M. Quantitative determinations of serum immunoglobulins in antibody agar plates. //J. Immunol. 1965. — vol.94. -P.84−90.
66. Fan Q., Uring-Lambert В., Weill B. Complement component C4 deficiencies and gene alterations in patient with systemic lupus erythematosus. //Eur. J. Immunogenet. 1993. — vol.20. — P. 11 -21.
67. Fearon D. Т., Austen K. F. Initiation of C3 cleavage in the alternative complement pathway. //J. Immunol. 1975. — vol.115, № 5. — P.1357−1361.
68. Fearon D. Т., Austen K. Properdin: initiation of alternative complement pathway. //Proc. Natl. Acad. Sci. U.S.A. 1975. — vol.72, № 8. — P.3220−3224.
69. Fisher В., Laycock C., Poole J., Powell H. A new alio anti-Ch specificity in a patient with a rare Ch positive phenotype Abstract. //Transfus. Med. -1993.-vol.3 (Suppl.) P.84.
70. Fischer M. В., Goerg S., Shen L. M. Dependence of germinal center B-cells on expression of CD21/CD35 for survival. //Science. 1998. — vol.280. -P.582−585.
71. Flexner S., Noguchi H. Snake venom in relation to haemolysis, bacteriolysis, and toxicity. //J. Exp. Med. 1902. — vol.6. — P.277−301.
72. Fujita Т., Tamura N. Interaction of C4-binding protein with cell-bound C4. A quantitative analysis of binding and the role of C4-binding in proteolysis of cell-bound C4b. //J. Exp. Med. 1983. — vol.157. -P.1239−1251.
73. Fujita Т., Satomura A., Hidaka M. Inhibitory effect of free sialic acid on complement activation and its significance in hypocomplementemic glomerulonephritis. //J. Clin. Lab. Anal. 1999. — vol.13, № 4. -P. 173−179.
74. Gadd K. J., Reid К. В. M. The binding of complement C3 to antibody-antigen aggregates after activation of alternative pathway in human serum. //Biochem. J. 1981. — vol.195. — P.471−480.
75. Gadjeva M., Thiel S., Jensenius J.C. The mannan-binding-lectin pathway of the innate immune system. //Curr. Opin. Immunol. 2001. — vol.13. — P.74−78.
76. Giles C.M. Gedde-Dahl Т., Robson E.B. Rga (Rodgers) and HLA region: linkage and associations. // Tissue Antigens. 1976. — vol.8. — P. 143−149.
77. Giles C.M. Antigens in plasma. //In: A Seminar on Antigens on Blood Cells and Body Fluids. Arlington: A ABB, 1980. P.33−49.
78. Giles C.M. A new genetic variant for Chido. // Vox Sang. 1984. — vol.46. -P.149−156.
79. Giles C.M., Swanson J.L. Anti-C4 in the serum of transfused C4-deficient patient with systemic lupus erythematosus. //Vox Sang. 1984. — vol.46. -P.291−299.
80. Giles C.M., Batchelor J.R., Dodi I.A. C4 and HLA haplotypes associated with partial inhibition of anti-Rg and anti-Ch. //J. Immunogenet. 1984. -vol.l 1. — P.305−317.
81. Giles C.M. «Partial inhibition» of anti-Rg and anti-Ch reagents. I. Assessment for Rg/Ch typing by inhibition. //Vox Sang. — 1985. vol.48. -P.160−166.
82. Giles C.M. «Partial inhibition» of anti-Rg and anti-Ch reagents. II. Demonstration of separable antibodies for different determinants. //Vox Sang. 1985.-vol.48.-P.167−173.
83. Giles C.M., Ford D.S. A monoclonal anti-C4d that demonstrates a specificity related to anti-Ch. //Transfusion. 1986. — vol.26. — P.370−374.
84. Giles C.M., Hoffman M., Moulds M. Allo-anti-Chido in a Ch-positive patient. //Vox Sang. 1987. — vol.52. — P. 129−133.
85. Giles C.M. Jones J.W. A new antigenic determinant for C4 of relatively low frequency. //Immunogenetics. 1987. — vol.26. — P.392−394.
86. Giles C.M., Fielder A.H.L., Lord D.K. Two monoclonal anti-C4d reagents reacts with epitopes closely related to Rg: l and Ch: l. //Immunogenetics. -1987. -vol.26. -P.309−312.
87. Giles C.M. Three Chido determinants detected on the B5Rg+ allotype of human C4: their expression in Ch-typed donors and families. //Hum. Immunol. 1987. — vol.18. — P. 111−122.
88. Giles C.M., Uring-Lambert В., Boksch W. The study of a French family with two duplicated C4A haplotypes. //Hum. Genet. 1987. — vol.77. — P.359−365.
89. Giles C.M., Tokunaga K., Zhang W.J. The antigenic determinants Rg/Ch/H, expressed by Japanese C4 allotypes. //J. Immunogenetics. 1988. — vol.15. — P.267−275.
90. Giles C.M., Uring-Lambert В., Goetz J. Antigenic determinants expressed by human C4 allotypes: a study of 325 families provides evidence for structural antigenic model. //Immunogenetics. 1988. — vol.27. — P.442−448.
91. Giles C.M. Antigenic determinants of human C4, Rodgers and Chido. //Exp. Clin. Immunogenet. 1988. — vol.5. — P.99−114.
92. Giles C.M., Davies K.A., Walport MJ. In vivo and in vitro binding of C4 molecules and agglutination. //Transfusion. 1991. — vol.31. — P.222−228.
93. Giles C.M., Robson T. Immunoblotting humanC4 bound to human erythrocytes in vivo and in vitro. //Clin. Exp. Immunol. 1991. — vol.84. — P.263−269.
94. Gordon D. L., Hostetter M. K. Complement and host defence against microorganisms. //Pathol. 1986. — vol.18. — P.365−375.
95. Gordon D. L., Jonson G. M., Hostetter M. K. Characteristics of iC3b binding to human polymorphonuclear leucocytes. //Immunol. 1987. — vol.60. — P.553−558.
96. G6tze O., Muller-Eberhard H.J. 1973. The role of properdin in the alternate pathway of complement activation. //J. Immunol. 1973. — vol.111. — P.288.
97. Harris J.P., Tegoli j., Swanson J. A nebulous antibody responsible for crossmatching difficulties (Chido). //Vox Sang. 1967. — vol.12. -P.140−142.
98. Heidelberger, M., Kendall F.E. The precipitation reaction between type III pneumococcus polysaccharide and homologous antibody III. A quantitative study and a theory of the reaction mechanism. //J. Exp. Med. 1935. — vol.61.-P.563−591.
99. Hellman U., Eggersten G., Lundwall A. Primary sequence differences between Chido and Rodgers variants of tryptic C4d on the human complement system. //FEBS. Lett. 1984. — vol.170. — P.254−258.
100. Hellwage J., Jokiranta T. S., Friese M. A. Complement C3b/C3d and cell surface polyanions are recognized by overlapping binding sites on the most carboxyl-terminal domain of complement factor H. //J. Immunol. 2002. — vol.169, № 12. — P.6935−6944.
101. Huang Y., Qiao F., Abagyan R. Defining the CD59-C9 binding interaction. //J. Biol. Chem. 2006. — vol.281, (37). -P.27 398−27 404.
102. Isenberg, H.D. Microbiology and Immunology: Parent and (Adult) Offspring. //Clin. Diagn. Lab. Immunol. 1999. — vol.6 (3). — P.287−288.
103. Issitt P.D., Anstee D.J. Applied Blood Group Serology, 4-th ed. Montgomery Sc. Publ., Durham, USA, 1998, 1250 P.
104. James J., Stiles P., Boyce F., Wright J. The HLA type of Rg (a-) individuals. //Vox Sang. 1976. — vol.30. — P.214−216.
105. Kapmeyer W. Nephelometric immunoassay with shell/core particles. //Pure & Appl. Chem. 1991.-vol. 63, № 8.-P.l 135−1139.
106. Kerr M. A. Limited proteolysis of complement components C2 and factor B. Structural analogy and limited sequence homology. //Biochem. J. 1979. — vol.183, ЖЗ.-Р.615−22.
107. Kerr M.A. The human complement system: assembly of the classical pathway C3 convertase. //Biochem. J. 1980. — vol.189, № 1. — P. 173−181.
108. Killings worth L. M., J. Savory J. Automated immunochemical procedures for measurement of immunoglobulins IgG, IgA and IgM in human serum. //Clin. Chem. 1971. — vol.17. — P.936−940.
109. Kirschfink M. Das serum komplement system. //Allergologie. — 1997. -vol.20, № 6. S.275−282.
110. Kirschfink M., Mollnes Т. E. Modern complement analysis. //Clin. Diagn. Lab. Immunol. 2003. — vol.10, № 6. — P.982−989.
111. Kishore U., Reid К. B. Clq: structure, function, and receptors. //Immunopharmacology 2000. — vol.49. — P. 159−170.
112. Koch A., M. Melbye P. Sorensen P. Acute respiratory tract infections and mannose-binding lectin insufficiency during early childhood. //JAMA. -2001.- vol.285. P. 1316−1321.
113. Kohl J. Anaphylatoxins and infectious and non-infectious inflammatory diseases. //Mol. Immunol. 2001. — vol.38. — P.175−187.
114. Koistinen V., Wessberg S., Leikola J. Common binding region of complement factor В, H and CR1 on C3b revealed by monoclonal anti-C3b. //Complement Inflamm. 1989. — vol.6. — P.270−280.
115. Kolb W. P., Muller-Eberhard H. J. The membrane attack complex of complement: isolation and subunit composition of C5b-C9 complex. //J. Exp. Med. 1975. — vol. 141. -P.724−735.
116. Lachmann P., Thompson J. R. A. Reactive lysis: the complement-mediated lysis of unsensitized cells: II. The characterization of activated reactor as C56 and the participation of C8 and C9. //J. Exp. Med. 1970. — vol.131. -P.643−657.
117. Lambin P., LePennec P.Y.,'Hauptmann G. Adverse transfusion reactions associated with a precipitating anti-C4 antibody of anti-Rodgers specificity. //Vox Sang. 1984. — vol.47. — P.242−249.
118. Lambris J.D. The third component of complement: chemistry and biology. 1990. Springer, Berlin.
119. Laurell C.B. Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. //Anal. Biochem. 1966. — vol.15. — P.45−52.
120. Law S.K.A., Reid K.B.M. Complement, 2nd ed., Oxford: IRL Press, 1995.
121. Linton S. M., Morgan B.P. Complement activation and inhibition in experimental models of arthritis. //Mol. Immunol. 1999. — vol.36. — P.905−914.
122. Linton S. M., Morgan B.P. Properdin deficiency and meningococcal disease-identifying those most at risk. //Clin. Exp. Immunol. 1999. -vol.118.-P.189−191.
123. Liszewski M. K., Leung M. K., Atkinson J. P. Membrane cofactor protein: importance of N- and O-giycosylation for complement regulatory function. //J. Immunol. 1998. — vol. 161 (7). — P.3711 -3718.
124. Lomas C.G., Green C.A., Akins C. A simple method for Ch and Rg testing. //Med. Lab. Sci. 1983. — vol.40. -P.65−66.
125. Longster G., Giles C.M. A new antibody specificity, anti-Rga, reacting with a red cell and serum antigen. //Vox Sang. 1976. — vol.30. — P. 175−180.
126. Lublin D. M., Kompelli S., Storry J. R. Molecular basis of Cromer blood group antigens. //Transfusion. 2000. — vol.40. — P.208−213.
127. Lundwall A., Hellman U., Eggersten G., Sjoquist J. Isolation of tryptic fragments of human C4 expressing Chido and Rodgers antigens. //Mol. Immunol. 1982. — vol.19. — P. 1655−1665.
128. Mancini G., Vaerman J. P., Carbonara A. O., Heremans J. F. A single radial diffusion method for the immunological quantitation of proteins.
129. Peters H, ed.) Proteids of biological fluids. Amsterdam. The Netherlands: Elsevier. 1964. — P.370−3.
130. Mancini G., Nash D. R., Heremans, J. F. Further studies on single radial immunodiffusion. III. Qualitative analysis of related and unrelated antigens. //Immunochem. 1970. — vol.7. — P.261−264.
131. Marshall P., Hasegawa A., Davidson E.A. Interaction between complement proteins C5b-7 and erythrocyte membrane sialic acid. //J. Exp. Med. 1994. -vol.184.-P.1225−1232.
132. Mastellos D., Andronis C., Persidis A., Lambris J. D. Novel biological networks modulated by complement. //Clin. Immunol. 2005. — vol.115. -P.225 -235.
133. Matsushita M., Fujita Т., Activation of the classical complement pathway by mannose-binding protein in association with a novel Cls-like serine protease. //J. Exp. Med. 1992. — vol.176. — P. 1497−1502.
134. Matsushita M., Takahashi A., Hatsuse H. Human mannose-binding protein is identical to a component of Ra-reactive factor. //Biochem. Biophys. Res. Communs. 1992. — vol.183, № 2. — P.645−651.
135. Matsushita M. The lectin pathway of the complement system. //Microbiol. Immunol. 1996. — vol.40. -P.887−893.
136. Matsushita M., Fujita T. The role of ficolins in innate immunity. //Immunobiol. 2002. — vol.205. — P.490−497.
137. Mauff G., Alper C.A., Awdeh Z. Statement on the nomenclature of human C4 allotypes. //Immunology. 1983. — vol.164. -P.184−191.
138. Mauff G., Bender K., Giles C.M. Human C4 polymorphism: pedigree analysis of qualitative, quantitative, and functional parameters as a basis for phenotype interpretations. //Hum. Genet. 1984. — vol.65. — 362−372.
139. Mauff G., Alper C.A., Dawkins R. C4 nomenclature statement (1990). //Complement Inflamm. 1990. — vol.7. -P.261−268.
140. Mauff G., Luther В., Schneider P.M. Reference report for complement component C4. //Exp. Clin. Immunogenet. 1998. — vol. l5. — P.249−260.
141. Mayer M. M. 1961. Complement and complement fixation. /An: Kabat E. A., Mayer M. M. eds. Experimental immunochemistry. Charles C. Thomas, Springfield, 111., 1961. -P.133−240.
142. Middleton J., Crookston M.C. Chido-substance in plasma. //Vox Sang. -1972.- vol.23. -P.256−261.
143. Middleton J.L. Anti-Chido: a crossmatching problem //Can. J. Med. Technol. 1972. — vol.34. — P.41−62.
144. Middleton J., Crookston M.C., Falk J.A. Linkage of Chido, HL-A. //Tissue Antigens. 1974. — vol.4. — P.366−373.
145. Мок С. С., Lau С. S. Pathogenesis of systemic lupus erythematosus. //J. Clin. Pathol. 2003. — vol.56. — P.481−490.
146. Mollison P.L., Polley M.J. Uptake of gamma-globulin and complement by red cells exposed to serum at low ionic strenght. //Nature. 1964. — vol.203 -P.535−536.
147. Mollnes E.L., Lachmann P.J. Regulation of complement. //Scand. J. Immunol. 1988. — vol.27, № 2. -P.127−142.
148. Molthan L. The Chido antigen: some developments Abstract., //Joint. Mtg. Am. Assoc. Blood Banks and Int. Soc. Haematol., 1972, P.57.
149. Morgan B. P. Physiology and pathophysiology of complement: progress and trends. //Crit. Rev. Clin. Lab. Sci. 1995. — vol.32 (5). — P.265−298.
150. Morgan B. P., Orren A. Vaccination against meningococcus in complement-deficient individuals. //Clin. Exp. Immunol. 1998. — vol.114. -P.327−329.
151. Morgan B.P., Harris C.L. 1999. Complement regulatory proteins. Academic Press, San Diego, 1999.
152. Morgan B. P.: Regulation of the complement membrane attack pathway. Crit. Rev. //Immunol. 1999. — vol.19. -P.173−198.
153. Moore H.C., Issitt P.D., Pavone B.G. Successful transfusion of Chido-positive blood to two patients with anti-Chido. //Transfusion. 1975. -vol.15.-P.266−269.
154. Moulds J.M. Association of blood group antigens with immunologically important proteins. //In: G. Garratty, ed. Immunobiology of Transfusion Medicine. N.Y.: Dekker, 1994. -P.273−297.
155. Moulds J.M., Roberts S.L., Wells T.D. DNA sequence analysis of the C4 antigen WH: evidence for two mechanisms of expression. //Immunogenetics.- 1996. vol.44. -P.104−107.
156. Mukherjee P., Pasinetti G.M. The role of complement anaphylatoxin C5a in neurodegeneration: implications in Alzheimer’s disease. //J. Neuroimmunol.- 2000. vol.105. — P. 124−130.
157. Muller-Eberhard H. J., Lepow I. H. CI esterase effect on activity and physicochemical properties of the fourth component of complement. //J. Exp. Med. 1965. — v.121. -P.819−833.
158. Muller-Eberhard H.J. Complement: molecular mechanisms, regulation and biological function. In: Molecular basis of biological degradative processes. Ed. By Berlin R. D. Hermann H., Lepow I.H., Tauser J.M. //New York: Acad. Press 1978.
159. Muller-Eberhard H. J., Shreiber R. D. Molecular biology and chemistry of the alternative pathway of complement. //Advanc. Immunol. 1980. -vol.29.-P. 1−53.
160. Muller-Eberhard H. J., The killer molecule of complement. //J. Invest. Dermatol. 1985. — vol.85 (Suppl. 1). -P.47−52.
161. Muller-Eberhard H. J. The membrane attack complex of complement. //Ann. Rev. Immunol. 1986. vol.4. — P. 134−138.
162. Nauta A. J., Bottazzi В., Mantovani A. Biochemical and functional characterization of the interaction between pentraxin 3 and Clq. //Eur. J. Immunol. 2003. — vol.33. -P.465−73.
163. Nonaka M. Evolution of the complement system. //Curr. Opin. Immunol. -2001.-vol.13.-P.69−73.
164. Nordhagen R., Heier Larsen A.M., Beckers D. Chido, Rodgers and C4: in vivo and in vitro coating of red blood cells, grouping and antibody detection. //Vox Sang. 1979. — vol.37. -P.l70−178.
165. Nordhagen R., Aas M. Survival studies of 51Cr Ch (a+) red blood cells in a patient with anti~Cha, and massive transfusion of incompatible blood. //Vox Sang. 1979. — vol.37. -P.242−249.
166. Nordhagen R., Olaisen В., Teisberg P., Gedde-Dahl T. Association between the electrophoretically-determined C4M haplotype product and partial inhibition of anti-Cha. //J. Immunogenet. 1980. — vol.7. — P.301−306.
167. Nordhagen R., Olaisen В., Teisberg P., Gedde-Dahl T. Heterogeneity of the Chido and Rodgers antigens. //Proc. 9 Int. Tagung. Gesellschaffr. Forens. Blutgruppenkunde. 1981. -P.507−517.
168. Nordhagen R., Olaisen В., Teisberg P. C4 haplotype products and partial inhibition of anti-Rodgers sera. //J. Immunogenet. 1981. — vol.8. — P.485−491.
169. Nuttall G. Experimente bber die bacterienfeindlichen Einflbsse des thierischen Кцгрегэ. //Medical Microbiology and Immunology. — 1888. -vol.4.-P.353−394.
170. Nzeako U. C., Frigas E., Tremaine W.J. Hereditary angioedema — a broad review for clinicians. //Arch. Intern. Med. 2001. — vol.161. — P.2417−2429.
171. Ohi H.3 Yasugi T. Occurrence of C3 nephritic factor and C4 nephritic factor in membranoproliferative glomerulonephritis (MPGN). //Clin. Exp. Immunol. 1994. — vol.95. — P.316−21.
172. Olaisen В., Teisberg P., Gedde-Dahl T. The C4 system: formal and popular genetics. //Hum. Genet. 1979. — vol.50. — P. l87−192.
173. O’Neill G.J., Yang S.Y., Dupont B. Two HLA-mke& loci controlling the fourth component of complement. //Proc. Natl. Acad. Sci. USA. — 1978. — vol.75.-P.5165−5169.
174. O’Neill G.J., Yang S.Y., Tegoli J., Berger R., Dupont B. Chido and Rodgers blood groups are distinct antigenic components of human complement C4. //Nature. 1978. — vol.273. — P.668−670.
175. O’Neill G.J., Berger R., Ballow M. Chido, Rodgers and C4 deficiency. //Transplant. Proc. 1979. — vol.11. — P. 1941−1943.
176. O’Neill G.J., The genetic control of Chido and Rodgers blood groups substances. //Semin. Hematol. 1981. — vol.18. -P.32−38.
177. Oudin J. La diffusion d’un antigene dans une colonne de gel contenant les anticorps precipitants homologoues: etude quantitative de trios principales variables. //C. R. Acad. Sci. 1949. — vol.228. -P.1890−1892.
178. Palsdottir A., Arnason A., Fossdal R., Jensson O. Gene organization of haplotypes expressing two different C4A allotypes. //Hum. Genet. 1987. -vol.76. -P.220−224.
179. Pangburn M. K., Muller-Eberhard H. J., Relation of the putative thioester bond in C3 to activation of the alternative pathway and the binding of C3b to biological targets of complement. //J. Exp. Med. 1980. — vol.152. — P. 102 114.
180. Pangbum M. K., Muller-Eberhard H. J. Kinetic and thermodynamic analysis of the control of C3b by the complement regulatory proteins factor H and factor I. //Biochem. 1983. — vol.22. -P.178−185.
181. Pangburn M. K., Muller-Eberhard H. J. The alternative pathway of complement. //Springer. Semin. Immunopathol. 1984. — vol.7. — P.163−192.
182. Pensky J. C. F. Hinz Jr., Todd E. W. Properties of highly purified human properdin. //J. Immunol. 1968. — vol.100. — P.142.
183. Pfeiffer R. Weitere Untersuchungen ueber das wesen der choleraimmunitat und ueber specifisch baktericide processe. //Ztschr. f. Hyg. u. Infektionskrankh. 1894. — XVIII. — S. l-16.
184. Pickering M. C., Walport M. J. Links between complement abnormalities and systemic lupus erythematosus. //Rheumatology. — 2000. vol.39 (2). — P.133−141.
185. Pickering M. C., Botto M, Taylor P. R. Systemic lupus erythematosus, complement deficiency and apoptosis. //Adv. Immunol. 2000. — vol.76. -P.227−324.
186. Pillemer L., Blum L., Lepow I. H. The properdin system and immunity. I. Demonstration and isolation of a new serum protein, properdin, and its role in immune phenomena. //Science. 1954. — vol.120 (3112). — P.279−285.
187. Pillemer L., Lepow I.H., Wurz L., Todd E.W. The properdin-system and immunity: III. The zymozan assay of properdin. //J. Exp. Med. — 1956. -vol.103.-P.l-14.
188. Poole J., Moulds J.M., Fisher B. Two Ch+ individuals with alio anti-Ch Abstract. //Transfusion. 1996. — vol.36. — 55S.
189. Porter R.R. Complement polymorphism, the major histocompatibility complex and associated diseases: a speculation. //Mol. Biol. Med. — 1983. -vol.1.-P.161−168.
190. Prodeus A. P. Zhou, X., Maurer M. Impaired mast cell-dependent natural immunity in complement C3-deficient mice. //Nature. 1997. — vol.390. -P.172−175.
191. Putzu G. A., Figarella-Branger D., Bouvier-Labit C. Immunohistochemical localization of cytokines, C5b-9 and ICAM-1 in peripheral nerve of Guillain-Barre syndrome. //J. Neurol. Sci. 2000. — vol. 174. — P.16−21.
192. Ramm L. E., Whitlow M. В., Mayer M. M. The relationship between channel size and the number of C9 molecules in the C5b-9 complex. //J. Immunol. 1985. — vol.134 (4). -P.2594−2599.
193. Rapp J. F., Borsos T. Molecular basis of complement action. Appleton Century Crofts, New York, N.Y. 1970.
194. Raum D., Awdeh Z., Andersen J. Human C4 haplotypes with duplicated C4A of C4B. //Am. J. Hum. Genet. 1984. — v.36. — P.72−79.
195. Rawal N., Pangburn M. К. C5 convertase of the alternative pathway of complement (kinetic analysis of free and surface-bound forms of the enzyme). //J. Biol. Chem. 1998. — vol.273, № 27. -P.16 828−16 835.
196. Rawal N., Pangburn M. K. Formation of high affinity C5 convertase of the classical pathway of complement. //J. Biol. Chem. 2003. — vol.278, № 40. -P.38 476−38 483.
197. Reca R., Mastellos D., Majka M. Functional receptor for C3a anaphylatoxin is expressed by normal hematopoietic stem/progenitor cells, and C3a enhances their homing-related responses to SDF-1. //Blood. 2003. — v.101. -P.3784−3793.
198. Reid R.B.V., Porter R. R. The proteolytic activation system of complement. //Ann. Rev. Biochem. 1981. — vol.50. -P.433−464.
199. Reveille J.D., Arnett F.C., Wilson R.W. Null alleles of the fourth component of complement and HLA haplotypes in familial systemic lupus erythematosus in three ethnic groups. //J. Immunogenet. 1985. — vol.21. -P.299−311.
200. Rittner C., Gils C.M., Roos M.H. Genetics of human C4 polymorphism: detection and segregation of rare and duplicated haplotypes. //Immunogenetics. 1984. — vol.19. — P.321−333.
201. Rittner Ch., Tippett P., Giles C.M. An international reference typing for Ch and Rg determinants on rare human C4 allotypes. //Vox Sang. — 1984. -vol.46. P.224−234.
202. Robson Т., Heard R.N.S., Giles C.M. An epitope on C4(3 light (L) chains detected by human anti-Rg- its relationship with (3 chain polymorphism and MHC associations. //Immunogenetics. 1989. — vol.30. — P.344−349.
203. Roos М.Н., Mollenhauer E., Demant P., Rittner C. A molecular basis for the two locus model of human complement component 4. //Nature. — 1982. -vol.29. -P.854−856.
204. Roos M.H., Giles C.M. Demant P. Rodgers (Rg) and Chido (Ch) determinants of human C4: characterization of two C4 B5 subtypes, one of which contains Rg and Ch determinants. //J. Immunol. 1984. — vol.133. -P.2634−2640.
205. Roos A., Bouwman L. H., van Gijlswijk-Janssen, D. J. //J. Immunol. -2001. vol.167. -P.2861−2868.
206. Rosenfield S.I., Ruddy S., Austen K.F. Structural polymorphism of the fourth component of human complement. //J. Clin. Invest. 1969. — vol.48. -P.2283−2292.
207. Rother K., Rother U. The reactivity of the complement system. //Prog. Allergy. 1986. — vol.39. -P.8−23.
208. Sahu A., Lambris J. D. Structure and biology of complement protein СЗ, a connecting link between innate and acquired immunity. //Immunol. Rev. 2001.-vol.180.-P.35−48.
209. Schenkel-Brunner H. Human blood groups. Chemical and biochemical basis of antigen specificity. 2nd ed., Springer, Wien, N.Y., 2000., 637 P.637.
210. Schumaker V. N., Zavodsky P., Poon P. H. Activation of the first component of complement. //Ann. Rev. Immunol. 1987. — vol.5. -P.21−42.
211. Sheehan M., Morris С. A., Pussell В. A., Charlesworth J. A. Complement inhibition by human vitronectin involves non-heparin binding domains. //Clin Exp. Immunol. 1995.-vol.101 (1).-P. 136−141.
212. Selander В., Martensson U., Weintraub A. Mannan-binding lectin activates C3 and the alternative complement pathway without involvement of C2. //J. Clin. Invest. 2006. — vol.116. — P. 1425−1434.
213. Sellebjerg F., Jaliashvili I., Christiansen M., Garred P. Intrathecal activation of the complement system and disability in multiple sclerosis. //J. Neurol. Sci. 1998. — vol.157. — P.68−74.
214. Silvergleid A.J., Wells R.F., Hafleigh E.B. Compatibility test using M Chromium-labeled red blood cells in cross-match positive patient. //Transfusion. 1978. — vol.18. -P.8−14.
215. Skanes V.M., Larsen В., Giles C.M. C4B3 allotype with a novel Ch phenotype. //Immunogenet. 1985. — vol.22. -P.609−616.
216. Smith L. C., Shin C. S., Dachenhausen, S. G. Coelomocytes express SpBf, a homologue of factor B, the second component in the sea urchin complement system. //J. Immunol. 1998. — vol.161, № 912. — P.6784−6793.
217. Song W-C., Sarrias M. R., Lambris J. D., Complement and innate immunity. //Immunopharmacol. 2000. — vol.49. — P. 187−198.
218. Strey C. W., Markiewski M., Mastellos D. The proinflammatory mediators C3a and C5a are essential for liver regeneration. //J. Exp. Med. 2003. -vol.198. -P.913−923.
219. Strohm P.L., Molthan L. Successful transfusion results using Rg (a+) blood in four patients with anti-Rga. //Vox Sang. 1983. — vol.45. — P.48−52.
220. Sunyer J. O., Tort L. Natural haemolytic and bactericidal activities of sea bream (Sparus aurata) are effected by the alternative complement pathway. //Vet. Immunol. Immunopathol. 1995. — vol.45. -P.333−345.
221. Swanson J.L. Laboratory problems associated with leukocyte antibodies. //In: A Seminar on Recent Advances in Immunohematology. Arlington: AABB, 1973, P.121−153.
222. Szalai A. J., Agrawal A., Greenhough T. J., Volankis J. E., C-reactive protein: structural biology, gene expression, and host defense function. //Immunol. Res. 1997. — vol.16. -P.127−136.
223. Szymanski I.O., Huff S.R., Delsignore R. An autoanalyzer test to determine immunoglobulin class and IgG subclass of blood group antibodies. //Transfusion. 1982. — vol.22. — P.90−95.
224. Takada F., Takayama Y., Hatsuse H., Kawakami M. A new member of the Cls family of complement proteins found in a bactericidal factor, Ra-reactive factor, in human serum. //Biochem. Biophys. Res. Commun. 1993. -vol.196.-P.1003−1009.
225. Teisberg P., Akeson I., Olaisen B. Genetic polymorphism of C4 in man and localization of a structural C4 locus to the HLA gene complex of chromosome 6. //Nature. 1976. — vol.264. — P.253−25.
226. Teisberg P., Jonassen R., Mevag B. Restriction fragment length polymorphisms of the complement component C4 loci on chromosome 6: studies with emphasis on the determination of gene number. //Ann. Hum. Genet. 1985. — vol.52. — P.77−84.
227. Thiel S., Holmskov U., Hviid, L. The concentration of the C-type lectin, mannan-binding protein, in human plasma increases during an acute phase response. //Clin. Exp. Immunol. 1992. — vol.90. — P.31−35.
228. Thiel S., Vorup-Jensen Т., Stover С. M. A second serine protease associated with mannan-binding lectin that activates complement. //Nature. -1997. -vol.386. -P.506−510.
229. Tilley C.A., Crookston M.C., Haddad S.A. Shumak K.H. Red blood cell survival studies in patients with anti-Cha, anti-Yka, anti-Ge, and anti-Vel. //Transfusion. 1977. — vol.17. — P. 169−172.
230. Tilley C.A., Romans D.G., Crookston M.C. Localization of Chido and Rodgers determinants to the C4d fragment of human C4. //Nature. 1978. -vol.276.-P.713−715.
231. Tippett P., Stony J.R., Walker P. S. Glycophorin A-deficient red cells may have a weak expression of C4-bound Ch and Rg antigens. //Immunohematology. 1996. — vol.12. — P.4−7.
232. Tomita A., Radike E. L., Parker C. J. Isolation of erythrocyte membrane inhibitor of reactive lysis type II. Identification as glycophorin A. //J. Immunol. 1993. — vol. 151. — P.3 308−3323.
233. Traube M. bber FAulnis und Widerstand der lebenden Organismen gegen dieselbe. Jahresbericht der Schles. Gesellschaft fer vaterl. //Cultur. 1874. — P. 179.
234. Tschopp J. Ultrastructure of the membrane attack complex of complement. Heterogeneity of the complex caused by different degree of C9 polymerization. //J. Biol. Chem. 1984. — vol.259 (12). -P.7857−7863.
235. Tschopp J., Podack E.R., Muller-Eberhard HJ. The membrane attack complex of complement: C5b-8 complex as accelerator of C9 polymerization. //J. Immunol. 1985. — vol.134 (1). -P.495−499.
236. Ulevitch R. J., Tobias P. S. Recognition of gram-negative bacteria and endotoxin by the innate immune system. //Curr. Opin. Immunol. 1999. — vol.11.-P. 19−22.
237. Van Weemen В. K., Schuurs A. H. W. M. Immunoassay using antigen-enzyme conjugates. //FEBS Letts. 1971. — vol.15. -P.232−236.
238. Volanakis J. E., Frank M.M. The human complement system in health and disease. Marcel Dekker, Inc., New York, N.Y., 1998.
239. Volankis J. E., Frank M. (Eds), The Chemistry and Biology of СЗ, C4, and C5. Marcel Dekker, N. Y. 1998.
240. Walport M. J., Davies K. A., Botto M. C3 nephritic factor and SLE: report of four cases and review of the literature. //Q. J. Med. 1994. — vol.87. — P.609−615.
241. Walport M. J. Complement — first of two parts. //N. Engl. J. Med. 2001. -vol.344. — P. 1058−1066.
242. Wang G., Liszewski M. K., Chan A. C., Atkinson J. P. Membrane cofactor protein (MCP- CD46): isoform-specific tyrosine phosphorylation. //J. Immunol. 2000. — vol.164 (4). — P. l839−1846.
243. Westhoff C.M., Sipherd B.D., Wylie D.E., Toalson L.D. Severe anaphylactic reactions following transfusions of platelets to a patient with anti-Ch. //Transfusion. 1992. — vol.32. -P.576−579.
244. Whitcher J. Т., Price C. P., Spencer K. Immunonephelometric and immunoturbidimetric assays for proteins. //Crit. Rev. Clin. Lab. Sci. 1983. -vol.18 (3).-P.213−60.
245. Wibaut В., Mannessier L., Horbez C. Anaphylactic reactions associated with anti-Chido antibody following platelet transfusions. //Vox Sang. 1995. -vol.69.-P.150−151.
246. Wilfert K., Atkins C.J., Tippett P. Ch and Rg antigens on sialidase treated red cells Abstract. //Transfus. Med. 1991. — vol.1 (Suppl.). — P.57.
247. WHO-IUIS Nomenclature Sub-Committee. Revised nomenclature for human complement component C4. //Eur. J. Immunogenet. 1993. — vol.20.- P.301−305.
248. Wolbink G. J., Brouwer M. C., Buysmann S. CRP-mediated activation of complement in vivo: assessment by measurement circulating complement-C-reactive protein complexes. //J. Immunol. 1996. — vol.157, № 1. — P.473−479.
249. Xia Y., Ross G. D. Roles of integrins CR3 and CR4 in disease and therapeutic strategies. //In: Lambris J. D., Holers V. M. eds. Therapeutic Interventions in the Complement system. Humana Press, Totawa, N J, USA., 2000.
250. Yalow R. S., Berson S. A. Immunoassay of endogenous plasma insulin in man. //Clin. Invest. I960. — vol.39. — P. 1157−1175.
251. Yu C.Y., Belr K.T., Giles C.M. Structural basis of the polymorphism of human complement components C4A and C4B: gene size, reactivity and antigenicity. //EMBO J. 1986. — vol.5. — P.2873−2881.
252. Yu C.Y., Campbell R.D., Porter R.R. A structural model for the location of the Rodgers and Chido antigenic determinants and their correlation with the human complement component C4A/C4B isotypes. //Immunogenetics. -1988. vol.27. -P.399−405.
253. Yu J., Abagyan R., Dong S. Mapping the Active Site of CD59. //J. Exp. Med. 1997. — vol.185 (4). — P.745−754.
254. Zalman L. S., Muller-Eberhard H. J. Comparison of channels formed by poly C9, C5b-8 and the membrane attack complex of complement. //Mol. Immunol. 1990. — vol.27 (6). — P.533−537.
255. Zalman L. S., Brothers M. A., Strauss K. L. Inhibition of cytolytic lymphocytes by homologous restriction factor. Lack of species restriction. //J. Immunol. 1991. — vol.146. -P.4278−4281.
256. Ziccardi R. J. The first component of human complement (CI): activation and control. //Springer Semin. Immunopathol. 1983. — vol.6 (2−3). — P.213−30.
257. Zinsser H., T. Parker J.T. Studies on bacterial anaphylaxis and infection. //J. Exp. Med. 1917. — vol.26. — P.411−435. /